Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
News & Press: Industry News for MS (INforMS)

CMSC INforMS: Novartis Statement on Reported Case of PML

Tuesday, June 9, 2015   (0 Comments)
Share |

Novartis Statement on Reported Case of PML

Novartis has been informed of a patient with progressive multifocal leukoencephalopathy (PML). The patient had been diagnosed with ulcerative colitis (an autoimmune bowel disease) in 2011 and had been treated with oral mesalazine since February 2011. At the end of 2012, the patient started treatment with Gilenya® (fingolimod) for the management of relapsing MS (RMS). This is the second case of PML in an MS patient being treated with Gilenya who did not haveprevious use of Tysabri® (natalizumab).



CMSC Disclaimer
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.


Sign In


Forgot your password?

Haven't registered yet?

Latest News
Upcoming Events

5/24/2017 » 5/27/2017
2017 CMSC Annual Meeting

5/30/2018 » 6/2/2018
2018 CMSC Annual Meeting

5/29/2019 » 6/1/2019
2019 CMSC Annual Meeting

3 University Plaza Drive, Suite 116
Hackensack, NJ 07601
Tel: 201-487-1050 | Fax: 862-772-7275
Privacy Policy | Disclaimer